reported that astragaloside IV could inhibit the proliferation of NSCLC cells, while astragaloside IV combined with chemotherapy could increase the sensitivity of tumor cells to gefitinib by regulating the level of SIRT6 in NSCLC cells (44). Here, SIRT6 is linked to non-small cell lung carcinoma.